Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis

Open Access Rheumatology: Research and Reviews

Volumn 3, Issue , 2011, Pages 19-29

  Mihara, Masahiko ^a   Ohsugi, Yoshiyuki ^a   Kishimoto, Tadamitsu ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Efficacy; Interleukin 6; Mode of action; Safety; Tocilizumab

Indexed keywords

COLLAGENASE 3; INTERLEUKIN 17; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RITUXIMAB; STROMELYSIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

AMYLOIDOSIS; ANEMIA; ANOREXIA; ARTICLE; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE MARKER; DIVERTICULOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROENTERITIS; HEPATITIS; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPERGAMMAGLOBULINEMIA; HYPOALBUMINEMIA; INTESTINE PERFORATION; JOINT DESTRUCTION; LIPID BLOOD LEVEL; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NEUTROPHIL COUNT; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PROTEIN EXPRESSION; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH ULCER; SYNOVITIS; TH17 CELL; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 79952945686     PISSN: None     EISSN: 1179156X     Source Type: Journal    
DOI: 10.2147/OARRR.S17118     Document Type: Article

References (80)

1. NICE. Rheumatoid Arthritis Consultation Document [Internet]. Available at: www.nice.org.uk. Accessed January 26, 2010.
2. Ohsugi Y, Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2008;8:669-681.
3. Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: An innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull. 2007;30:2001-2006.
4. Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53:851-856.
5. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and soluble interleukin-6 receptor, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731-1740.
6. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19: 12-19.
7. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised, controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-1167.
8. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010; 69:88-96.
9. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: Tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-2980.
10. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987-997.
11. Kremer JL, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE study. Arthritis Rheum. 2010; November 19. [Epub ahead of print].
12. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-1523.
13. Yamanaka H, Tanaka Y, Inoue E, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: Results from a retrospective study (REACTION study). Mod Rheumatol. 2010; October 16. [Epub ahead of print].
14. Hirabayashi Y, Ishii T, Harigae H. Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int. 2010;30:1041-1048.
15. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an antiinterleukin- 6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68: 1580-1584.
16. Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: Subanalysis of the SATORI study. Mod Rheumatol. 2010;20:539-547.
17. Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19: 507-512.
18. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants. Arthritis Rheum. 2011;63:43-52.
19. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: Meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222-232.
20. Van Vollenhoven RF, Keystone EC, Furie R, Blesch A, Wang C, Curtis JR. Gastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: Data from Roche clinical trials. Abstr 1613. Arthritis Rheum. 2009;60 Suppl:S602.
21. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-2829.
22. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: A review of its use in the management of rheumatoid arthritis. Drugs. 2009;69:609-632.
23. Van Vollenhoven RF, Scali JJ, Curtis JR, et al. Safety of tocilizumab in patients with rheumatoid arthritis: Analysis of median of 3.1 years of treatment in long-term extension studies. Poster SAT0172 presented at the European League against Rheumatism Annual European Congress of Rheumatology, Rome, Italy, June 16-19, 2010.
24. Van Gameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: A phase I-II study. Blood. 1994;84:1434-1441.
25. Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993;11:499-506.
26. Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol. 2005;32:252-255.
27. Dursunoglu D, Evrengül H, Polat B, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation. Rheumatol Int. 2005;25:241-245.
28. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: A challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68: 460-469.
29. Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M. Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low- density lipoprotein receptor. Ann Rheum Dis. 2010; 69:741-746.
30. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64:303-305.
31. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31:784-788.
32. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232-234.
33. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1-78.
34. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D. Angiogenesis in rheumatoid arthritis. Histol Histopathol. 2006;21:557-566.
35. Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48:1521-1529.
36. Hashizume M, Hayakawa N, Suzuki M, Mihara M. IL-6/soluble interleukin- 6 receptor trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int. 2009;29:1449-1454.
37. Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull. 2008;31:1159-1163.
38. Suzuki M, Hashizume M, Yoshida H, Mihara M. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: Effect on the expression of chemokine and adhesion molecule. Rheumatol Int. 2010;30:309-315.
39. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol. 1995;34:321-325.
40. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford). 2008;47:1635-1640.
41. Sagawa A. The effect of short term treatment of anti-IL-6 receptor antibody tocilizumab on signs and symptoms and synovial inflammation in patients with active rheumatoid arthritis. Ann Rheum Dis. 2010;69 Suppl 3:539.
42. Fujikawa Y, Shingu M, Torisu T, Itonaga I, Masumi S. Bone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synovium. Br J Rheumatol. 1996;35: 213-217.
43. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43:250-258.
44. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93:165-176.
45. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323.
46. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43:259-269.
47. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, doubleblind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008; 58:1299-1309.
48. Hashizume M, Mihara M. Desirable effect of combination therapy with high molecular weight hyaluronate and nonsteroidal anti-inflammatory drugs on MMP production. Osteoarth Cartil. 2009;17:1513-1518.
49. Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. Cytokine. 2010;51:178-183.
50. Hashimoto J, Garnero P, van der Heijde D, et al. Humanized antiinterleukin- 6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: Data from the SAMURAI study. Mod Rheumatol. June 24, 2010. [Epub ahead of print].
51. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum. 2010;62:33-43.
52. Kawashiri SY, Kawakami A, Iwamoto N, et al. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics. Mod Rheumatol. 2010;20:40-45.
53. Baer AN, Dessypris EN, Goldwasser E, Krantz SB. Blunted erythropoietin response to anemia in rheumatoid arthritis. Br J Haematol. 1987; 66:559-564.
54. Hochberg MC, Arnold CM, Hogans BB, Spivak JL. Serum immunoreactive erythropoietin in rheumatoid arthritis: Impaired response to anemia. Arthritis Rheum. 1988;31:1318-1321.
55. Jongen-Lavrencic M, Peeters HR, Wognum A, Vreugdenhil G, Breedveld FC, Swaak AJ. Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. J Rheumatol. 1997;24:1504-1509.
56. Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol. 1999;92: 153-160.
57. Uchiyama Y, Koike N, Mihara M. Anemia in monkey collagen-induced arthritis is correlated with serum IL-6, but not TNF alpha. Rheumatol Int. 2008;28:879-883.
58. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783-788.
59. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood. 2005;106: 2196-2199.
60. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A. 2002;99:4596-4601.
61. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-1276.
62. Hashizume M, Uchiyama Y, Horai N, Tomosugi N, Mihara M. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int. 2010;30:917-923.
63. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-238.
64. Iwanami K, Matsumoto I, Tanaka-Watanabe Y, et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum. 2008;58: 754-763.
65. Fujimoto M, Serada S, Mihara M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 2008;58:3710-3719.
66. Yoshida H, Hashizume M, Mihara M. IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis. Rheumatol Int. 2011;31:127-131.
67. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med. 2008;205:2491-2497.
68. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol. 2008;20:1361-1368.
69. Zhang C, Zhang J, Yang B, Wu C. Cyclosporin A inhibits the production of IL-17 by memory Th17 cells from healthy individuals and patients with rheumatoid arthritis. Cytokine. 2008;42:345-352.
70. Papagoras C, Voulgari CV, Drosos AA. Strategies after the failure of the first anti-tumor necrosis factor a agent in rheumatoid arthritis. Autoimmun Rev. 2010;9:574-582.
71. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739-1745.
72. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc. 2006;295:2275-2285.
73. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328-346.
74. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54: 2997-3000.
75. Husby G. Treatment of amyloidosis and the rheumatologist. State of the art and perspectives for the future. Scand J Rheumatol. 1998;27: 161-165.
76. Del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44: 2737-2745.
77. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314:363-369.
78. Van Vollenhoven RF, Nishimoto N, Yamanaka H, et al. Experience with mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database. Ann Rheum Dis. 2009;68 Suppl 3:557.
79. Ogata A, Mori M, Hashimoto S, et al. Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens. Mod Rheumatol. 2010;20:130-133.
80. Ohsugi Y, Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2008;8:669-681.